CORE TECHNOLOGIES

Biosimilar therapeutic monoclonal Antibodies (mAb)

Chemotherapy, while killing cancer cells also damages healthy cells leading to severe side effects, such as the, nausea, vomiting, loss of hair and extreme fatigue. mAb-based treatment targets specifically cancer cells thus eliminating side effects and has been established as one of the most successful therapeutic strategies in the 20 years. Virocan has developed clones for biosimilar mAb for which either patent expired and soon to be expired. They are suitable for the treatment of cancers and immune system disorders like arthritis. Virocan developed clones for several other mAb ready for pre-clinical trials.